Developmental Regulation of Mitochondrial Apoptosis by c-Myc Governs Age- and Tissue-Specific Sensitivity to Cancer Therapeutics

Cancer Cell. 2017 Jan 9;31(1):142-156. doi: 10.1016/j.ccell.2016.11.011. Epub 2016 Dec 22.

Abstract

It is not understood why healthy tissues can exhibit varying levels of sensitivity to the same toxic stimuli. Using BH3 profiling, we find that mitochondria of many adult somatic tissues, including brain, heart, and kidneys, are profoundly refractory to pro-apoptotic signaling, leading to cellular resistance to cytotoxic chemotherapies and ionizing radiation. In contrast, mitochondria from these tissues in young mice and humans are primed for apoptosis, predisposing them to undergo cell death in response to genotoxic damage. While expression of the apoptotic protein machinery is nearly absent by adulthood, in young tissues its expression is driven by c-Myc, linking developmental growth to cell death. These differences may explain why pediatric cancer patients have a higher risk of developing treatment-associated toxicities.

Keywords: apoptosis; c-Myc; cardiotoxicity; cell death regulation; chemosensitivity; neurotoxicity; pediatric cancer; radiosensitivity; side effects of chemotherapy; side effects of radiation therapy.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural

MeSH terms

  • Age Factors
  • Animals
  • Apoptosis*
  • Doxorubicin / toxicity
  • Humans
  • Mice
  • Mitochondria / physiology*
  • Neoplasms / drug therapy*
  • Neoplasms / pathology
  • Organ Specificity
  • Proto-Oncogene Proteins c-myc / physiology*
  • bcl-2 Homologous Antagonist-Killer Protein / physiology
  • bcl-2-Associated X Protein / physiology

Substances

  • MYC protein, human
  • Proto-Oncogene Proteins c-myc
  • bcl-2 Homologous Antagonist-Killer Protein
  • bcl-2-Associated X Protein
  • Doxorubicin